PepGen Inc
PEPG1.880USD
-0.170-8.29%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
61.66MCap. mercado
PérdidaP/E TTM
Más Datos de PepGen Inc Compañía
PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.
Información de la empresa
Símbolo de cotizaciónPEPG
Nombre de la empresaPepGen Inc
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoDr. James G. Mcarthur, Ph.D.
Número de empleados81
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 06
Dirección245 Main St, 2nd Floor
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Teléfono17034568000
Sitio Webhttps://pepgen.com
Símbolo de cotizaciónPEPG
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoDr. James G. Mcarthur, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Mr. Noel P. Donnelly
Mr. Noel P. Donnelly
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Joshua B. (Josh) Resnick, M.D.
Dr. Joshua B. (Josh) Resnick, M.D.
Independent Director
Independent Director
--
--
Dr. Howard Mayer, M.D.
Dr. Howard Mayer, M.D.
Independent Director
Independent Director
--
--
Dr. Kasra Kasraian, Ph.D.
Dr. Kasra Kasraian, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. James G. Mcarthur, Ph.D.
Dr. James G. Mcarthur, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
53.19K
+3040.14%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
4.17K
--
Ms. Mary Beth Delena, J.D.
Ms. Mary Beth Delena, J.D.
General Counsel, Company Secretary
General Counsel, Company Secretary
1.43K
-8.67%
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Director
Independent Director
--
--
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
--
--
Dr. Paul D. Streck, M.D.
Dr. Paul D. Streck, M.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 19 de ago
Actualizado: mar., 19 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
32.59%
Oxford Science Enterprises PLC
14.50%
Point72 Asset Management, L.P.
8.41%
Millennium Management LLC
4.60%
Viking Global Investors LP
4.52%
Otro
35.38%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
32.59%
Oxford Science Enterprises PLC
14.50%
Point72 Asset Management, L.P.
8.41%
Millennium Management LLC
4.60%
Viking Global Investors LP
4.52%
Otro
35.38%
Tipos de accionistas
Accionistas
Proporción
Venture Capital
47.09%
Hedge Fund
26.11%
Investment Advisor/Hedge Fund
6.31%
Investment Advisor
5.65%
Sovereign Wealth Fund
3.79%
Research Firm
0.53%
Individual Investor
0.27%
Otro
10.24%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
165
31.28M
95.59%
-5.47M
2025Q1
168
31.44M
96.09%
-5.26M
2024Q4
160
31.09M
95.12%
-3.10M
2024Q3
156
31.41M
96.35%
-1.62M
2024Q2
150
31.22M
97.59%
-974.84K
2024Q1
140
30.76M
96.24%
+4.98M
2023Q4
127
22.26M
93.52%
+3.25M
2023Q3
124
22.70M
95.37%
+3.35M
2023Q2
119
23.17M
97.35%
+3.81M
2023Q1
108
18.62M
78.36%
-609.71K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
10.69M
32.67%
--
--
Mar 31, 2025
Oxford Science Enterprises PLC
4.76M
14.53%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.68M
8.18%
+804.74K
+43.01%
Mar 31, 2025
Millennium Management LLC
1.03M
3.16%
+876.38K
+559.50%
Mar 31, 2025
Viking Global Investors LP
1.48M
4.53%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
1.35M
4.13%
+550.00K
+68.75%
Mar 31, 2025
Qatar Investment Authority
1.24M
3.8%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
899.73K
2.75%
-12.94K
-1.42%
Mar 31, 2025
Laurion Capital Management LP
810.76K
2.48%
--
--
Mar 31, 2025
Woodline Partners LP
780.90K
2.39%
+780.90K
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
iShares Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
Proshares Ultra Russell 2000
Proporción0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0%
ProShares UltraPro Russell2000
Proporción0%
iShares Micro-Cap ETF
Proporción0%
Invesco Nasdaq Biotechnology ETF
Proporción0%
ProShares Hedge Replication ETF
Proporción0%
iShares Biotechnology ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
